Literature DB >> 2301923

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.

M M Mouradian1, I J Heuser, F Baronti, T N Chase.   

Abstract

The management of fluctuations in motor function complicating advanced Parkinson's disease with continuously administered dopaminomimetics was studied in 12 patients. In response to 7 to 12 days of round-the-clock intravenous infusions of levodopa, fluctuations in motor performance gradually diminished, ultimately by more than 40%. The beneficial effect persisted for about 6 days after withdrawal of continuous parenteral treatment and resumption of standard oral therapy. Clinical improvement was associated with changes in several pharmacological indices: Acute dose-response studies of intravenous levodopa showed a shift of the curve to the right in the immediate postinfusion phase compared to preinfusion studies; the therapeutic index improved significantly as patients demonstrated about 76% increased beneficial antiparkinsonian response with an equal degree of toxic dyskinetic effects; and the duration of action of levodopa was prolonged by 30%. These results suggest that changes in central dopaminergic mechanisms contributing to motor complications in advanced Parkinson's disease can be modified by procedures that provide continuous dopamine replacement. Presumably these modifications underlie the gradual amelioration of motor fluctuations over several days of round-the-clock therapy. Results of the present study also suggest potential deleterious effects of chronic intermittent oral treatment in the development of motor complications and thus support the role of long-term, continuous administration of dopaminomimetics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301923     DOI: 10.1002/ana.410270105

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Case report: successful use of rectally administered levodopa-carbidopa.

Authors:  S D Cooper; H A Ismail; C Frank
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

2.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

3.  Parkinson's Disease: Motor Fluctuations.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

4.  Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.

Authors:  Cristina Sampaio; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

5.  Characterization of the 5' flanking region of the human D1A dopamine receptor gene.

Authors:  M T Minowa; T Minowa; F J Monsma; D R Sibley; M M Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  The impact of subthalamic deep brain stimulation on bradykinesia of proximal and distal upper limb muscles in Parkinson's disease.

Authors:  Manuel Dafotakis; Gereon R Fink; Niels Allert; Dennis A Nowak
Journal:  J Neurol       Date:  2008-03-19       Impact factor: 4.849

Review 7.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.

Authors:  Emilie Lacombe; Carole Carcenac; Sabrina Boulet; Claude Feuerstein; Anne Bertrand; Annie Poupard; Marc Savasta
Journal:  Eur J Neurosci       Date:  2007-09-06       Impact factor: 3.386

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.